Malaria vaccine (MSP3CRMV4All) - Vac4All
Alternative Names: MSP3-CRM-Vac4All/ Alhydrogel®-Vac4All; MSP3CRMV4AllLatest Information Update: 04 May 2023
At a glance
- Originator Vac4All
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Falciparum malaria
Most Recent Events
- 27 Mar 2023 Phase-I/II clinical trials in Falciparum malaria (Prevention, In infants, In children) in Mali (IM) (NCT05776017)
- 07 Mar 2023 Vac4All plans a phase I/II trial for Falciparum malaria (Prevention, In infants, In children) in Mali (IM) (NCT05776017)
- 01 Dec 2021 Phase-I clinical trials in Falciparum malaria (Prevention, In adults) in Mali (IM) (NCT05197751)